High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype

Jennifer B. Dennison, Maria Shahmoradgoli, Wenbin Liu, Zhenlin Ju, Funda Meric-Bernstam, Charles M. Perou, Aysegul A. Sahin, Alana Welm, Steffi Oesterreich, Matthew J. Sikora, Robert E. Brown, Gordon Mills

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The current study evaluated associative effects of breast cancer cells with the tumor microenvironment and its influence on tumor behavior. Experimental Design: Formalin-fixed, paraffin-embedded tissue and matched protein lysates were evaluated from two independent breast cancer patient datasets (TCGA and MD Anderson). Reverse-phase protein arrays (RPPA) were utilized to create a proteomics signature to define breast tumor subtypes. Expression patterns of cell lines and normal breast tissues were utilized to determine markers that were differentially expressed in stroma and cancer cells. Protein localization and stromal contents were evaluated for matched cases by imaging. Results: A subtype of breast cancers designated "Reactive," previously identified by RPPA that was not predicted by mRNA profiling, was extensively characterized. These tumors were primarily estrogen receptor (ER)-positive/human EGF receptor (HER)2-negative, low-risk cancers as determined by enrichment of low-grade nuclei, lobular or tubular histopathology, and the luminal A subtype by PAM50. Reactive breast cancers contained high numbers of stromal cells and the highest extracellular matrix content typically without infiltration of immune cells. For ER-positive/HER2-negative cancers, the Reactive classification predicted favorable clinical outcomes in the TCGA cohort (HR, 0.36; P < 0.05). Conclusions: A protein stromal signature in breast cancers is associated with a highly differentiated phenotype. The stromal compartment content and proteins are an extended phenotype not predicted by mRNA expression that could be utilized to subclassify ER-positive/HER2-negative breast cancers.

Original languageEnglish (US)
Pages (from-to)5068-5078
Number of pages11
JournalClinical Cancer Research
Volume22
Issue number20
DOIs
StatePublished - Oct 15 2016
Externally publishedYes

Fingerprint

Breast Neoplasms
Estrogen Receptors
Protein Array Analysis
Neoplasms
Proteins
Phenotype
Messenger RNA
Tumor Microenvironment
Stromal Cells
Epidermal Growth Factor Receptor
Paraffin
Proteomics
Formaldehyde
Extracellular Matrix
Breast
Research Design
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype. / Dennison, Jennifer B.; Shahmoradgoli, Maria; Liu, Wenbin; Ju, Zhenlin; Meric-Bernstam, Funda; Perou, Charles M.; Sahin, Aysegul A.; Welm, Alana; Oesterreich, Steffi; Sikora, Matthew J.; Brown, Robert E.; Mills, Gordon.

In: Clinical Cancer Research, Vol. 22, No. 20, 15.10.2016, p. 5068-5078.

Research output: Contribution to journalArticle

Dennison, JB, Shahmoradgoli, M, Liu, W, Ju, Z, Meric-Bernstam, F, Perou, CM, Sahin, AA, Welm, A, Oesterreich, S, Sikora, MJ, Brown, RE & Mills, G 2016, 'High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype', Clinical Cancer Research, vol. 22, no. 20, pp. 5068-5078. https://doi.org/10.1158/1078-0432.CCR-16-0171
Dennison, Jennifer B. ; Shahmoradgoli, Maria ; Liu, Wenbin ; Ju, Zhenlin ; Meric-Bernstam, Funda ; Perou, Charles M. ; Sahin, Aysegul A. ; Welm, Alana ; Oesterreich, Steffi ; Sikora, Matthew J. ; Brown, Robert E. ; Mills, Gordon. / High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 20. pp. 5068-5078.
@article{7ffd91fe2e344875a4982becd80ef156,
title = "High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype",
abstract = "Purpose: The current study evaluated associative effects of breast cancer cells with the tumor microenvironment and its influence on tumor behavior. Experimental Design: Formalin-fixed, paraffin-embedded tissue and matched protein lysates were evaluated from two independent breast cancer patient datasets (TCGA and MD Anderson). Reverse-phase protein arrays (RPPA) were utilized to create a proteomics signature to define breast tumor subtypes. Expression patterns of cell lines and normal breast tissues were utilized to determine markers that were differentially expressed in stroma and cancer cells. Protein localization and stromal contents were evaluated for matched cases by imaging. Results: A subtype of breast cancers designated {"}Reactive,{"} previously identified by RPPA that was not predicted by mRNA profiling, was extensively characterized. These tumors were primarily estrogen receptor (ER)-positive/human EGF receptor (HER)2-negative, low-risk cancers as determined by enrichment of low-grade nuclei, lobular or tubular histopathology, and the luminal A subtype by PAM50. Reactive breast cancers contained high numbers of stromal cells and the highest extracellular matrix content typically without infiltration of immune cells. For ER-positive/HER2-negative cancers, the Reactive classification predicted favorable clinical outcomes in the TCGA cohort (HR, 0.36; P < 0.05). Conclusions: A protein stromal signature in breast cancers is associated with a highly differentiated phenotype. The stromal compartment content and proteins are an extended phenotype not predicted by mRNA expression that could be utilized to subclassify ER-positive/HER2-negative breast cancers.",
author = "Dennison, {Jennifer B.} and Maria Shahmoradgoli and Wenbin Liu and Zhenlin Ju and Funda Meric-Bernstam and Perou, {Charles M.} and Sahin, {Aysegul A.} and Alana Welm and Steffi Oesterreich and Sikora, {Matthew J.} and Brown, {Robert E.} and Gordon Mills",
year = "2016",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-16-0171",
language = "English (US)",
volume = "22",
pages = "5068--5078",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype

AU - Dennison, Jennifer B.

AU - Shahmoradgoli, Maria

AU - Liu, Wenbin

AU - Ju, Zhenlin

AU - Meric-Bernstam, Funda

AU - Perou, Charles M.

AU - Sahin, Aysegul A.

AU - Welm, Alana

AU - Oesterreich, Steffi

AU - Sikora, Matthew J.

AU - Brown, Robert E.

AU - Mills, Gordon

PY - 2016/10/15

Y1 - 2016/10/15

N2 - Purpose: The current study evaluated associative effects of breast cancer cells with the tumor microenvironment and its influence on tumor behavior. Experimental Design: Formalin-fixed, paraffin-embedded tissue and matched protein lysates were evaluated from two independent breast cancer patient datasets (TCGA and MD Anderson). Reverse-phase protein arrays (RPPA) were utilized to create a proteomics signature to define breast tumor subtypes. Expression patterns of cell lines and normal breast tissues were utilized to determine markers that were differentially expressed in stroma and cancer cells. Protein localization and stromal contents were evaluated for matched cases by imaging. Results: A subtype of breast cancers designated "Reactive," previously identified by RPPA that was not predicted by mRNA profiling, was extensively characterized. These tumors were primarily estrogen receptor (ER)-positive/human EGF receptor (HER)2-negative, low-risk cancers as determined by enrichment of low-grade nuclei, lobular or tubular histopathology, and the luminal A subtype by PAM50. Reactive breast cancers contained high numbers of stromal cells and the highest extracellular matrix content typically without infiltration of immune cells. For ER-positive/HER2-negative cancers, the Reactive classification predicted favorable clinical outcomes in the TCGA cohort (HR, 0.36; P < 0.05). Conclusions: A protein stromal signature in breast cancers is associated with a highly differentiated phenotype. The stromal compartment content and proteins are an extended phenotype not predicted by mRNA expression that could be utilized to subclassify ER-positive/HER2-negative breast cancers.

AB - Purpose: The current study evaluated associative effects of breast cancer cells with the tumor microenvironment and its influence on tumor behavior. Experimental Design: Formalin-fixed, paraffin-embedded tissue and matched protein lysates were evaluated from two independent breast cancer patient datasets (TCGA and MD Anderson). Reverse-phase protein arrays (RPPA) were utilized to create a proteomics signature to define breast tumor subtypes. Expression patterns of cell lines and normal breast tissues were utilized to determine markers that were differentially expressed in stroma and cancer cells. Protein localization and stromal contents were evaluated for matched cases by imaging. Results: A subtype of breast cancers designated "Reactive," previously identified by RPPA that was not predicted by mRNA profiling, was extensively characterized. These tumors were primarily estrogen receptor (ER)-positive/human EGF receptor (HER)2-negative, low-risk cancers as determined by enrichment of low-grade nuclei, lobular or tubular histopathology, and the luminal A subtype by PAM50. Reactive breast cancers contained high numbers of stromal cells and the highest extracellular matrix content typically without infiltration of immune cells. For ER-positive/HER2-negative cancers, the Reactive classification predicted favorable clinical outcomes in the TCGA cohort (HR, 0.36; P < 0.05). Conclusions: A protein stromal signature in breast cancers is associated with a highly differentiated phenotype. The stromal compartment content and proteins are an extended phenotype not predicted by mRNA expression that could be utilized to subclassify ER-positive/HER2-negative breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=84991594403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991594403&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-0171

DO - 10.1158/1078-0432.CCR-16-0171

M3 - Article

C2 - 27172895

AN - SCOPUS:84991594403

VL - 22

SP - 5068

EP - 5078

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -